middle.news
How Amplia’s Narmafotinib Is Changing Pancreatic Cancer Outcomes
9:46am on Monday 23rd of March, 2026 AEDT
•
Healthcare
Read Story
How Amplia’s Narmafotinib Is Changing Pancreatic Cancer Outcomes
9:46am on Monday 23rd of March, 2026 AEDT
Key Points
Five complete responses (7.8%) confirmed in ACCENT trial
Median overall survival extended to 11.1 months
Objective response rate updated to 35.9%
No additional toxicity observed with narmafotinib combination
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE